Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Genitourinary 1

Conditions

Carcinoma, Renal Cell 11Prostatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Kidney Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Neoplasms 1

Interventions

pembrolizumab 28Docetaxel 21Gemcitabine 19Nivolumab 14Paclitaxel 13Prednisone 11Leuprolide 11pazopanib 10Radiotherapy 10Cisplatin 10Sunitinib 9Sorafenib 9Ipilimumab 8Blood Specimen Collection 8Bevacizumab 8avelumab 7Therapeutics 7Thalidomide 7Cyclophosphamide 7Carboplatin 7atezolizumab 6Standard of Care 6Radiation 6Mitomycin 6Interleukin-2 6Cetuximab 6Axitinib 6padeliporfin 5cemiplimab 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Introns × Genitourinary × Clear all
NCT00485563 2012-03-08

A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma

Endocyte

Phase 2 Terminated
12 enrolled
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡